definiens: ) to theORIGINAL LICENSE as defined below, is made by and between the BOARD OF REGENTS ( ) of THE UNIVERSITYOF TEXAS SYSTEM ( ), an agency of the State of Texas, whose address is 201 West 7th Street, Austin, Texas78701, on behalf of THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER ( hereafter ), acomponent institution of SYSTEM, and ARONEX PHARMACEUTICALS, INC ., a Delaware corporation having a principalplace of business located at 3 Forbes Road, Lexington, Massachusetts 02421 ( ), a wholly owned subsidiary ofANTIGENICS INC ., a Delaware corporation . BOARD and LICENSEE may be referred to hereafter collectively as theRECITALS A. BOARD and ARGUS PHARMACEUTICALS, INC ., executed an Exclusive License Agreement dated effective as ofJuly 22, 1988 ( such Exclusive License Agreement, as amended, referred to herein as the ) ; B. LICENSEE is the successor in interest to ARGUS PHARMACEUTICALS, INC . ; C. The PARTIES have reached an agreement to return rights to certain technologies to BOARD ( as defined below ) ; D. The PARTIES have further agreed that LICENSEE will provide certain information relating to the RETURNEDTECHNOLOGY to UTMDACC;NOW, THEREFORE, in consideration of the mutual covenants contained herein, the sufficiency of which is herebyacknowledged, the parties hereby agree to the following : AMENDED TERMS 1 . Schedule Ito the ORIGINAL LICENSE is hereby amended to exclude the RETURNED TECHNOLOGY ( as definedbelow ) . The amended Schedule I is attached hereto